| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Otitis Media | D010033 | 12 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Stjepanovic MI et al. | Pulmonary and Vertebral Mycobacterium avium Disease in a HIV-negative 71-year-old Man - A Case Report. | 2016 | Infez Med | pmid:28011973 |
| Ramzy I et al. | GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. | 2016 | Rev. Inst. Med. Trop. Sao Paulo | pmid:27982354 |
| Muñoz-Egea MC et al. | Effect of Antibiotics and Antibiofilm Agents in the Ultrastructure and Development of Biofilms Developed by Nonpigmented Rapidly Growing Mycobacteria. | 2016 | Microb. Drug Resist. | pmid:26208145 |
| Abuhammour A et al. | Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. | 2016 | Arab J Gastroenterol | pmid:27665525 |
| Matsumoto H et al. | Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. | 2016 | Dig. Dis. Sci. | pmid:27659671 |
| Kasai C et al. | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. | 2016 | BMC Gastroenterol | pmid:27716077 |
| Gisbert JP | Helicobacter pylori-related diseases. | 2016 | Gastroenterol Hepatol | pmid:27888863 |
| Noda H et al. | A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. | 2016 | J Gastrointestin Liver Dis | pmid:27689190 |
| Donzelli A | Helicobacter pylori Eradication? | 2016 | Gastroenterology | pmid:27590693 |
| Rossi A et al. | Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. | 2016 | Drug Dev Ind Pharm | pmid:26065531 |
| Harada T et al. | Premedication with Clarithromycin Is Effective against Secondary Bacterial Pneumonia during Influenza Virus Infection in a Pulmonary Emphysema Mouse Model. | 2016 | J. Pharmacol. Exp. Ther. | pmid:27489022 |
| Bonfigli AR et al. | Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. | 2016 | Nutr Metab Cardiovasc Dis | pmid:27480449 |
| Orrin E et al. | Sporotrichoid Mycobacterium chelonae. | 2016 | Australas. J. Dermatol. | pmid:27469486 |
| Yamamoto K et al. | Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3. | 2016 | Pharmacol. Res. | pmid:27468646 |
| Ferro BE et al. | Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. | 2016 | Antimicrob. Agents Chemother. | pmid:27458221 |
| Patton PH et al. | Anti-tuberculous therapy for maintenance of remission in Crohn's disease. | 2016 | Cochrane Database Syst Rev | pmid:27444319 |
| Christl I et al. | Clarithromycin and Tetracycline Binding to Soil Humic Acid in the Absence and Presence of Calcium. | 2016 | Environ. Sci. Technol. | pmid:27438991 |
| Luo XF et al. | Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori. | 2016 | World J. Gastroenterol. | pmid:27433095 |
| Hirasawa K et al. | Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines. | 2016 | PLoS ONE | pmid:27977675 |
| Mougari F et al. | Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. | 2016 | Expert Rev Anti Infect Ther | pmid:27690688 |
| Mitchell H and Katelaris P | Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. | 2016 | Med. J. Aust. | pmid:27256648 |
| Ullah S et al. | Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. | 2016 | Drug Deliv | pmid:27247018 |
| Kuo CH et al. | A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. | 2016 | Medicine (Baltimore) | pmid:27227911 |
| Sluch IM et al. | Mycobacterium chelonae Scleral Abscess After Intravitreal Ranibizumab Injection. | 2016 | Cornea | pmid:27227391 |
| Laird-Fick HS et al. | Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts. | 2016 | Postgrad Med J | pmid:27222587 |
| Phiphatpatthamaamphan K et al. | Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study. | 2016 | Asian Pac. J. Cancer Prev. | pmid:27221874 |
| Xu J et al. | Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit(®) L-100 microspheres. | 2016 | Eur J Drug Metab Pharmacokinet | pmid:25652786 |
| Song ZQ et al. | Hybrid Therapy Regimen for Helicobacter Pylori Eradication. | 2016 | Chin. Med. J. | pmid:27064046 |
| Matsumoto H et al. | Molecular Detection of H. pylori Using Adherent Gastric Mucous to Biopsy Forceps. | 2016 | Helicobacter | pmid:27061611 |
| Tsaganos T et al. | Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. | 2016 | Antimicrob. Agents Chemother. | pmid:27044546 |
| Buchicchio A et al. | Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD). | 2016 | Sci. Total Environ. | pmid:27039063 |
| Melia MT and Auwaerter PG | Time for a Different Approach to Lyme Disease and Long-Term Symptoms. | 2016 | N. Engl. J. Med. | pmid:27028918 |
| Berende A et al. | Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. | 2016 | N. Engl. J. Med. | pmid:27028911 |
| D'Erme AM et al. | Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone. | 2016 | Int. J. Dermatol. | pmid:27028670 |
| Klesiewicz K et al. | Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone. | 2016 | J. Antibiot. | pmid:27025351 |
| Kawashima K et al. | Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy. | 2016 | Dig Liver Dis | pmid:27012448 |
| Belz D et al. | Mycobacterium marinum infection initially diagnosed as metastatic Crohn's disease. | 2016 | J Eur Acad Dermatol Venereol | pmid:25510444 |
| Tepeš B et al. | Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. | 2016 | Eur J Gastroenterol Hepatol | pmid:26862930 |
| Lim SG et al. | The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. | 2016 | Dig Liver Dis | pmid:26856963 |
| Niv Y | Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. | 2016 | Digestion | pmid:26849820 |
| Song Z et al. | Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. | 2016 | Dig Liver Dis | pmid:26847964 |
| Vannarath S et al. | Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. | 2016 | Asian Pac. J. Cancer Prev. | pmid:26838225 |
| Miyamoto S et al. | Analysis of Helicobacter pylori genotypes in clinical gastric wash samples. | 2016 | Tumour Biol. | pmid:26825980 |
| Bohnert JA et al. | Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. | 2016 | Antimicrob. Agents Chemother. | pmid:26824939 |
| Meng Y et al. | Multi-functional Liposomes Enhancing Target and Antibacterial Immunity for Antimicrobial and Anti-Biofilm Against Methicillin-Resistant Staphylococcus aureus. | 2016 | Pharm. Res. | pmid:26666773 |
| Konstantinidis T et al. | Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. | 2016 | Antimicrob. Agents Chemother. | pmid:26643338 |
| Ferro BE et al. | Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. | 2016 | Antimicrob. Agents Chemother. | pmid:26643335 |
| Wu TS et al. | Postcesarean section wound infection caused by Mycobacterium massiliense. | 2016 | J Microbiol Immunol Infect | pmid:26350122 |
| Mark TM and Coleman M | It's Time to Take Clarithromycin Seriously in Multiple Myeloma. | 2016 | Acta Haematol. | pmid:26505907 |
| Qiu XH et al. | Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells. | 2016 | Acta Haematol. | pmid:26505646 |
| Senatore FJ et al. | Helicobacter pylori treatment: Still a work in progress. | 2016 | Postgrad Med | pmid:26490697 |
| Shin WG et al. | Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. | 2016 | Helicobacter | pmid:26470999 |
| Narita M et al. | Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions. | 2016 | Bull. Tokyo Dent. Coll. | pmid:27665691 |
| Ghaith D et al. | Mutations affecting domain V of the 23S rRNA gene in Helicobacter pylori from Cairo, Egypt. | 2016 | J Chemother | pmid:26358218 |
| Yoon H et al. | Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. | 2016 | Gut Liver | pmid:26347514 |
| Liou JM et al. | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of in the community and hospital populations: a randomised trial. | 2016 | Gut | pmid:26338825 |
| Jenkins H et al. | Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. | 2017 | Clin Drug Investig | pmid:27928738 |
| Mishima E et al. | Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. | 2017 | Intern. Med. | pmid:28674358 |
| Sun W et al. | Synergistic drug combination effectively blocks Ebola virus infection. | 2017 | Antiviral Res. | pmid:27890675 |
| Shimoyama T et al. | Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. | 2017 | Intern. Med. | pmid:28674348 |
| Hung IFN et al. | Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. | 2017 | Chest | pmid:27884765 |
| Ustundag GH et al. | The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. | 2017 | Can J Gastroenterol Hepatol | pmid:28656129 |
| Peng X et al. | Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. | 2017 | Int J Med Sci | pmid:28638276 |
| Ozturk O et al. | Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. | 2017 | Arab J Gastroenterol | pmid:28601610 |
| Aguilera-Correa JJ et al. | Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. | 2017 | Diagn. Microbiol. Infect. Dis. | pmid:27863951 |
| Alirezaei A et al. | Helicobacter pylori Eradication With Levofloxacin or Clarithromycin in Dialysis Versus Nonuremic Patients. | 2017 | Iran J Kidney Dis | pmid:28575885 |
| Cosme A et al. | Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. | 2017 | World J. Gastroenterol. | pmid:28566898 |
| Angol DC et al. | from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. | 2017 | Biomed Res Int | pmid:28555193 |
| Ivanová L et al. | Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka. | 2017 | Environ. Res. | pmid:28183039 |
| Varma MV et al. | Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. | 2017 | Clin. Pharmacol. Ther. | pmid:27648490 |
| Huet D et al. | [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. | 2017 | Rev Mal Respir | pmid:27639948 |
| El Haj C et al. | The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance? | 2017 | Med. Microbiol. Immunol. | pmid:27639707 |
| Jia L et al. | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. | 2017 | Bioorg. Med. Chem. Lett. | pmid:28711353 |
| Seyama S et al. | Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). | 2017 | J. Antimicrob. Chemother. | pmid:27999037 |
| Zerbetto De Palma G et al. | Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. | 2017 | Microb. Drug Resist. | pmid:27391421 |
| Legendre T et al. | [Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. | 2017 | Encephale | pmid:27178256 |
| Choi HS et al. | Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. | 2017 | Jpn. J. Infect. Dis. | pmid:27169951 |
| Serrano CA et al. | Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. | 2017 | J. Pediatr. Gastroenterol. Nutr. | pmid:27159208 |
| Pastukh N et al. | GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. | 2017 | Helicobacter | pmid:29058343 |
| Tognetti L et al. | Bullous impetigo during interstitial pneumonitis. | 2017 | G Ital Dermatol Venereol | pmid:29050448 |
| Chen MJ et al. | Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. | 2017 | J. Antimicrob. Chemother. | pmid:28961996 |
| Kim SY et al. | Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. | 2017 | Helicobacter | pmid:28940815 |
| Mukherjee D et al. | Vancomycin and Clarithromycin Show Synergy against . | 2017 | Antimicrob. Agents Chemother. | pmid:28923867 |
| Antonakos N et al. | Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. | 2017 | Crit Care | pmid:28274246 |
| Koratala A et al. | Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. | 2017 | Blood Purif. | pmid:28268216 |
| Lin CM et al. | Is ionizing radiation a risk factor to diffuse panbronchiolitis? | 2017 | QJM | pmid:28069906 |
| Fraser AG | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776748 |
| Jung YS et al. | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776746 |
| Makihara K et al. | Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. | 2017 | Cancer Chemother. Pharmacol. | pmid:28711984 |
| Tanabe H et al. | Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. | 2017 | Dig. Dis. Sci. | pmid:28664410 |
| Fohner AE et al. | PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. | 2017 | Pharmacogenet. Genomics | pmid:28146011 |
| Sue S et al. | The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. | 2017 | Intern. Med. | pmid:28566587 |
| Sakurai K et al. | Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. | 2017 | World J. Gastroenterol. | pmid:28216974 |
| Awan S et al. | Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. | 2017 | Lung Cancer | pmid:28213005 |
| Su J et al. | Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. | 2017 | Medicine (Baltimore) | pmid:28207505 |
| Branquinho D et al. | Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? | 2017 | BMC Gastroenterol | pmid:28202013 |
| Inukai K et al. | Effect of gel formation on the dissolution behavior of clarithromycin tablets. | 2017 | Int J Pharm | pmid:28196716 |
| Miftahussurur M et al. | Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic. | 2017 | Am. J. Trop. Med. Hyg. | pmid:28193745 |
| Zhang Z et al. | In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. | 2017 | Int. J. Antimicrob. Agents | pmid:28188830 |
| Kristin F et al. | Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. | 2017 | Eur J Pharm Sci | pmid:28179133 |